Show simple item record

AuthorSafieh-Garabedian B.
AuthorNomikos M.
AuthorSaade N.
Available date2020-03-18T10:47:17Z
Publication Date2019
Publication NameNeuroscience Letters
AbstractNeuropathic pain is considered to be pathological in nature and has been shown to involve, at least partially, dysregulated inflammatory processes. It is a severe chronic disease that can develop following lesions to the central nervous system or to peripheral nerves. The peripheral nerve damage can be caused by either diseases such as diabetes, or by trauma. A common underlying mechanism of neuropathic pain is the presence of inflammation at the site of the damaged or affected nerve(s). This inflammatory response, especially when unresolved, initiates and maintains a cascade of events resulting in the activation of innate immune cells at the site of tissue injury. The release of inflammatory mediators such as cytokines, neurotrophic factors, and chemokines initiates local actions and can result in a more generalized immune response. The resultant neuroinflammatory environment can cause activation of glial cells, which can release, in an uncontrolled manner, more of these mediators and exasperate the situation, thus having a prominent role in nociception. The neuropathic pain pathophysiology is complex and includes peripheral and central neuronal alterations as well as neuro-immune interactions, which become more prominent during inflammatory reactions. This report focuses on how targeting inflammatory mediators may result in novel therapeutic approaches to neuropathic pain management.
PublisherElsevier Ireland Ltd
SubjectImmune system
SubjectNeuropathic pain
SubjectPeptide analogue of thymulin
TitleTargeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide
TypeArticle Review
Volume Number702

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record